Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Solvay Sells Pharma Division to Abbott for $7.6B

By Pharmaceutical Processing | September 28, 2009

BRUSSELS (AP) — Solvay, the Belgian chemical and pharmaceutical group, said Monday it has agreed to sell its entire pharmaceutical business to Abbott Laboratories of Abbott Park, Illinois, for euro5.2 billion ($7.6 billion). The American company already holds U.S. marketing rights for Solvay’s Trilipix and TriCor, drugs which raise “good” HDL cholesterol while reducing triglycerides and “bad” LDL cholesterol. Solvay said in a statement the sale will let it “refocus” its activities, which also cover chemicals and plastics. Solvay said the price Abbott will pay for its pharmaceutical operations includes euro4.5 billion ($6.6 billion) in cash, additional “potential payments” of up to euro300 million ($439 million) and liabilities estimated at euro400 million ($584 million). It said the sale will be completed in the first quarter of 2010, pending antitrust approval from the EU and U.S. “We are building a new refocused group with the financial means to further accelerate sustainable growth,” Alois Michielsen, Solvay’s chairman, said. Abbott makes and markets pharmaceutical and medical products in more than 130 countries and employs more than 72,000 people. In the last year, it has bought contact lens maker Advanced Medical Optics, India-based Wockhart’s nutritional business, eye care company Synchrony and Evalve, a maker of heart repair equipment. Solvay Pharmaceuticals is a group of companies that employs 9,000 people worldwide and had sales of euro2.7 billion in 2008. The Solvay Group as a whole employs more than 29,000 people in 50 countries. Its 2008 consolidated sales were euro9.5 billion.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE